Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, ...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...

A woman receiving an IV at the hospital. This article is part of an ongoing series on novel cancer advances, including immunotherapies such as CAR T therapy and checkpoint inhibitors. Future ...

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

A multi-agency sobriety checkpoint on Highway 80 resulted in five DWI arrests and numerous other citations as law enforcement ...

As the High Desert prepares to celebrate the nation's 250th anniversary, deputies in Victorville are planning a sobriety ...